Paclitaxel and carboplatin chemotherapy in patients with metaststic melanoma refractory to BRAF/MEK inhibitors.

被引：0
|
作者：
Samoylenko, Igor
Kharkevich, Galina
Petenko, Natalia N.
Orlova, Kristina V.
Sinelnikov, Igor
Utyashev, Igor A.
Vikhrova, Anastasia
Markina, Irina
Demidov, Lev V.
机构：
[1] NN Blokhin Russian Canc Res Ctr, Moscow, Russia
[2] IM Sechenov First Moscow State Med Univ, Moscow, Russia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.9552
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9552
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Patients with stage IV melanoma with BRAF mutation - immunotherapy or BRAF and MEK inhibitors in first line therapy?
    Cybulska-Stopa, Bozena
    Ziobro, Marek
    ONCOLOGY IN CLINICAL PRACTICE, 2018, 14 : A9 - A12
  • [22] The "SWOT" of BRAF Inhibition in Melanoma: RAF Inhibitors, MEK Inhibitors or Both?
    Nissan, Moriah H.
    Solit, David B.
    CURRENT ONCOLOGY REPORTS, 2011, 13 (06) : 479 - 487
  • [23] Concurrent MEK2 Mutation and BRAF Amplification Confer Resistance to BRAF and MEK Inhibitors in Melanoma
    Villanueva, Jessie
    Infante, Jeffrey R.
    Krepler, Clemens
    Reyes-Uribe, Patricia
    Samanta, Minu
    Chen, Hsin-Yi
    Li, Bin
    Swoboda, Rolf K.
    Wilson, Melissa
    Vultur, Adina
    Fukunaba-Kalabis, Mizuho
    Wubbenhorst, Bradley
    Chen, Thomas Y.
    Liu, Qin
    Sproesser, Katrin
    DeMarini, Douglas J.
    Gilmer, Tona M.
    Martin, Anne-Marie
    Marmorstein, Ronen
    Schultz, David C.
    Speicher, David W.
    Karakousis, Giorgos C.
    Xu, Wei
    Amaravadi, Ravi K.
    Xu, Xiaowei
    Schuchter, Lynn M.
    Herlyn, Meenhard
    Nathanson, Katherine L.
    CELL REPORTS, 2013, 4 (06): : 1090 - 1099
  • [24] The “SWOT” of BRAF Inhibition in Melanoma: RAF Inhibitors, MEK Inhibitors or Both?
    Moriah H. Nissan
    David B. Solit
    Current Oncology Reports, 2011, 13 : 479 - 487
  • [25] BRAF/MEK inhibition in melanoma patients with rare BRAF mutations
    Hassel, Jessica Cecile
    Menzer, Christian
    Menzies, Alexander M.
    Carlino, Matteo S.
    Long, Georgina V.
    Kefford, Richard
    Eigentler, Thomas K.
    Johnson, Douglas Buckner
    Schlaak, Max
    Meiss, Frank
    Schilling, Bastian
    Gutzmer, Ralf
    Pfoehler, Claudia
    Meier, Friedegund Elke
    Zimmer, Lisa
    Haalck, Thomas
    Thoms, Kai
    Kopp-Schneider, Annette
    Enk, Alexander
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [26] Patient with stage IV melanoma with BRAF mutation - immunotherapy or BRAF and MEK inhibitors?
    Cybulska-Stopa, Bozena
    Ziobro, Marek
    ONCOLOGY IN CLINICAL PRACTICE, 2018, 14 (02): : 100 - 103
  • [27] Combined inhibition of BRAF and MEK in melanoma patients
    Infante, Jeffrey R.
    Swanton, Charles
    LANCET ONCOLOGY, 2014, 15 (09): : 908 - 910
  • [28] BRAF, MEK and KIT inhibitors for melanoma: adverse events and their management
    Livingstone, Elisabeth
    Zimmer, Lisa
    Vaubel, Julia
    Schadendorf, Dirk
    CHINESE CLINICAL ONCOLOGY, 2014, 3 (03)
  • [29] Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma
    Ziogas, Dimitrios C.
    Konstantinou, Frosso
    Bouros, Spyros
    Theochari, Maria
    Gogas, Helen
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2021, 22 (03) : 301 - 314
  • [30] Conjunctival Melanoma Responsive to Combined Systemic BRAF/MEK Inhibitors
    Glass, Lora R. Dagi
    Lawrence, Donald P.
    Jakobiec, Frederick A.
    Freitag, Suzanne K.
    OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY, 2017, 33 (05): : E114 - E116
12345